Neuraly is a clinical stage biopharmaceutical company founded by scientists and physicians with a worldwide reputation in the field of neurodegenerative diseases.

Our mission is to translate scientific discoveries in neurology into revolutionary new drugs that can radically change improve and prolong the lives of people suffering from the devastating consequences of diseases such as Parkinson’s disease, Alzheimer’s disease and other neurodegenerative disorders. At present, these are diseases that even with the use of available state-of-the-art treatments, are chronic, progressive, and fatal. Unfortunately, even many of the new drugs in development have only the potential to temporarily reduce symptoms. For today’s patients, both quality of life and life expectancy remain dramatically compromised by these diseases. Families and whole communities find the joys of longevity cut short and destroyed.

Neuraly was founded to develop new drugs with potential to change our expectations about successful treatment of progressive diseases like Alzheimer’s and Parkinson’s. This is our bar. We are developing treatments for neurodegenerative diseases that offer new hope, that address new pathways, that capitalize on our founder’s innovation and deliver medicines with the potential to change lives.